GORE® VIABIL® Short Wire Biliary Endoprosthesis

Now in a new short wire delivery system, the self-expanding GORE® VIABIL® Short Wire Biliary Endoprosthesis is the only fully-covered metal stent with anti-migration technology proven to minimize the risk of reintervention. Additionally, it offers substantiated evidence in studies that demonstrate sustained long-term patency^5,6 :

Demonstrated low migrations - Fully covered anchoring fins

Securely holds the device within the duct to minimize the risk of migration, with a reported 0–1.4% migration rate range outperforming BOSTON SCIENTIFIC WALLFLEX Biliary RX Fully Covered Stent migration rates ranging up to 0–13%.¹

Optimal Conformability - Nitinol Wire based stent design

Optimal balance of Radial and Axial force provides the right fit and flexibility to help prevent migration and sludge formation.^3,4

Prevents tissue ingrowth and promotes conformability - Durable, non-porous FEP / ePTFE liner

Proven highest patency helps provide a high standard of palliative care for your patients.^5,6

Higher primary patency

Clinical performance demonstrates GORE® VIABIL® Biliary Endoprosthesis maintains higher primary patency than the leading competitor at 3, 6, and 12-months.^5,6
Improved long-term patency can mean an improved quality of life for patients.

CONMED Biliary Assurance Program

With a 0.2% average reported migration rate, we’re so confident in these outcomes we will replace it* if a migration occurs.

*Subject to terms and conditions, MCM2017139
¹W. L. Gore & Associates, Inc. Migration Summary for GORE® VIABIL® Biliary Endoprosthesis and BOSTON SCIENTIFIC WALLFLEX Biliary RX Fully Covered Stent.
Flagstaff, AZ: W. L. Gore & Associates, Inc; 2017. [Literature Summary]. AW0010-EN3.
²W. L. Gore & Associates, Inc. Reduce the risk of reintervention. GORE® VIABIL® Biliary Endoprosthesis Assurance Brochure. Flagstaff, AZ: W. L. Gore & Associates, Inc;
2017. [Flyer]. AW0165-EN1.
³Isayama H, Mukai T, Itoi T, et al. Comparison of partially covered nitinol stents with partially covered stainless stents as a historical control in a multicenter study of distal malignant biliary obstruction: the WATCH study. Gastrointestinal Endoscopy 2012;76(1):84-92.
4Isayama H, Nakai Y, Toyokawa Y, et al. Measurement of radial and axial forces of biliary self-expandable metallic stents. Gastrointestinal Endoscopy 2009;70(1):37-44.
⁵Kitano M, Yamashita Y, Tanaka K, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013 Nov;108(11):1713-22.
⁶Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovascular & Interventional Radiology 2010;33(1):97-106.